RMC-0708: An Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective Tri-Complex Inhibitor — Drug/Modality/Target Intelligence Dossier
How a second macrocycle turned a 2.5-fold starting point into RMC-0708 — an orally bioavailable, >200-fold KRAS Q61H-selective RAS(ON) tri-complex inhibitor, with the deposited co-crystal to prove it.
Read article →